Background-Neuregulins are required for maintenance of acetylcholine receptor-inducing activity of nicotinic receptors in neurons and skeletal muscle, but effects of neuregulins on muscarinic receptors are not known. In the normal heart, parasympathetic activation counterbalances ␤-adrenergic activation. To test the hypothesis that neuregulins modify parasympathetic function in the heart, we studied cardiomyocytes from mice heterozygous for neuregulin-1 gene deletion (NRG-1 ϩ/Ϫ ) and examined the effects of ␤-adrenergic stimulation on contractility in the presence and absence of the muscarinic agonist carbachol.
N euregulins are growth factors that interact with a subclass of tyrosine kinase receptors within the epidermal growth factor family, including erbB2 and erbB4 receptors in the heart. [1] [2] [3] Neuregulins promote cell growth, differentiation, and survival during normal development and healing during injury 4, 5 and are essential for embryonic cardiac development. 6 Interference with the oncogenic properties of neuregulins has been exploited in cancer chemotherapy with the use of trastuzumab, a monoclonal antibody against the erbB2 receptor.
Cancer patients treated with trastuzumab in addition to doxorubicin have a higher risk of developing severe heart failure than those treated with doxorubicin alone. 7, 8 We demonstrated that left ventricular (LV) erbB2 and erbB4 protein levels are decreased in experimental heart failure 9 and that mice with conditional erbB2 mutation develop cardiomyopathy. 10, 11 These data support the concept that neuregulin-erbB signaling is cardioprotective, but the responsible mechanisms are incompletely understood.
One major biological effect of neuregulin signaling in the nervous system is the maintenance of nicotinic acetylcholine receptors (acetylcholine receptor-inducing activity [ARIA]). 12, 13 In cardiac tissue, it is not known whether neuregulins also regulate parasympathetic muscarinic receptors or their activation. The inability to activate muscarinic receptors might interfere with the normal cardioprotective parasympathetic modulation of excess ␤-adrenergic stimulation.
To test the hypothesis that neuregulins modify parasympathetic function in the heart, we studied cardiomyocytes from mice heterozygous for neuregulin-1 gene deletion (NRG-1 ϩ/Ϫ ) and examined the effects of ␤-adrenergic stimulation on contractility in the presence and absence of the muscarinic agonist carbachol. We also investigated the possible mechanisms involved downstream of the muscarinic receptor.
Methods

Measurement of Myocyte Contraction and Intracellular Ca 2؉
We studied LV myocytes from 10-to 14-week-old NRG-1 ϩ/Ϫ and wild-type (WT) mice used as controls (nϭ9 animals per group). This transgenic mouse was created by Meyer and Birchmeier 6 by deletion of exons 7, 8, and 9 of the EGF domain of the neuregulin-1 gene and used to generate mice heterozygous for neuregulin-1 gene deletion. These NRG-1 ϩ/Ϫ animals exhibit normal postnatal viability and cardiac development in the absence of a superimposed injury. 6 In the present experiment, LV myocytes were dissociated and loaded with the Ca 2ϩ -sensitive fluorescence indicator Fluo-3. Cell contraction and [Ca 2ϩ ] i transients were then measured simultaneously with a video and fluorescence microscopy system following methods described in detail from our laboratory. 14 Myocytes were paced with field stimulation at 0.5 Hz with 1.5 mmol/L [Ca 2ϩ ] o at 25°C. First, after at least 5 minutes of stabilization, myocytes were stimulated with 1 mol/L isoproterenol for 3 minutes (WT, nϭ33 myocyte experiments from 9 hearts; NRG-1 ϩ/Ϫ , nϭ41 experiments from 9 hearts). Next, the myocytes were randomized to be stimulated with isoproterenol for an additional 6 minutes (WT, nϭ16 myocyte experiments from 9 hearts; NRG-1 ϩ/Ϫ , nϭ20 experiments from 9 hearts) or with stepped changes in carbachol (10 mol/L followed by 100 mol/L for 3 minutes at each concentration) in the presence of isoproterenol (WT, nϭ17 myocyte experiments from 9 hearts; NRG-1 ϩ/Ϫ , nϭ21 experiments from 9 hearts). In additional experiments, the effects of carbachol in the absence of isoproterenol were studied (nϭ20 myocyte experiments from 8 hearts). All of the experimental procedures were approved and conducted in conformity with guidelines of the Institutional Animal Care and Use Committee.
cAMP Measurements cAMP levels were determined in freshly isolated myocytes stimulated with 1 mol/L isoproterenol alone (10 minutes at 37°C) or plus 100 mol/L carbachol (15 minutes before isoproterenol at 37°C), with the use of a commercially available enzyme immunoassay system (RPN225-Amersham Biosciences) and according to the protocol provided by the company. Myocytes isolated from each LV were divided in 6 wells (control: average of 2 wells; isoproterenol alone: average of 2 wells; isoproterenolϩcarbachol: average of 2 wells) (WT, nϭ6 experiments from 6 hearts; NRG-1 ϩ/Ϫ , nϭ5 experiments from 5 hearts).
Western Blotting
LV sarcolemmal plasma membranes and LV and brain lysates were prepared, and Western blotting was performed. 9, 15 The following antibodies were used to measure levels of LV proteins: antimuscarinic AChR-M 2 (Santa Cruz Biotechnology); anti-G protein subunits G␣ i1,2 , G␣ i3 , and G␣ o (Calbiochem); and anti-endothelial NO synthase (eNOS) and anti-inducible NO synthase (iNOS) (BD Biosciences). Protein levels of the nicotinic receptor AChR-␤ 1 (Santa Cruz Biotechnology) were investigated in brain lysates. The Western Blot Lightning-Chemiluminescence Reagent Plus (Perkin-Elmer Life Sciences) was used to detect bound antibodies. Protein levels were normalized to those of GAPDH (nϭ5 mice per group).
Statistical Analysis
Values are expressed as meanϮSEM. Comparisons among the groups were analyzed by ANOVA followed by a post hoc test. Two-way ANOVA with repeated measures was used to compare the response of myocytes to isoproterenol with and without carbachol. Student t test was used to compare 2 groups. Statistical significance was accepted at the level of PϽ0.05.
Results
The body weight (24.2Ϯ0.64 versus 27.7Ϯ1.99 g; PϭNS) and LV weight/body weight ratio (6.83Ϯ0.15 versus 6.80Ϯ0.33 mg/g; PϭNS) were similar in NRG-1 ϩ/Ϫ and WT mice. The total number of myocyte experiments and baseline characteristics are shown in Table 1 . Myocyte diastolic length and area and parameters of cell contraction/relengthening and systolic/diastolic [Ca 2ϩ ] i transients were similar between the groups. There was no effect of carbachol alone on any parameter. Isoproterenol (1 mol/L) alone caused similar augmentation of fractional shortening (FS), dL/dt, and peaksystolic [Ca 2ϩ ] i in both groups ( Table 2 ). Figure 1 shows the effects of the addition of carbachol in the presence of isoproterenol stimulation in comparison with isoproterenol stimulation alone in WT and NRG-1 ϩ/Ϫ myocytes. In WT myocytes stimulated with isoproterenol, carbachol caused a concentration-dependent depression of both FS (PϽ0.001) and peak-systolic [Ca 2ϩ ] i (Pϭ0.001) in comparison with WT myocytes stimulated continuously with isoproterenol alone. In contrast, in NRG-1 ϩ/Ϫ myocytes stimulated with isoproterenol, carbachol failed to attenuate either FS (PϭNS) or peak-systolic [Ca 2ϩ ] i (PϭNS) in comparison with isoproterenol alone (Figure 1 ). As shown, in WT myocytes, 
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Muscarinic Receptor in NRG-1 ؉/؊ Mice isoproterenol-stimulated FS (13.5Ϯ0.81% versus 15.6Ϯ0.85%) and peak-systolic [Ca 2ϩ ] i (542Ϯ34 versus 691Ϯ52 nmol/L) were depressed in presence versus absence of 100 mol/L carbachol. As shown, in NRG-1 ϩ/Ϫ myocytes, isoproterenolstimulated FS (16.7Ϯ0.66% versus 15.9Ϯ0.84%) and peak-systolic [Ca 2ϩ ] i (640Ϯ43 versus 650Ϯ56 nmol/L) were similar in presence versus absence of 100 mol/L carbachol. In WT and NRG-1 ϩ/Ϫ myocytes, basal control levels of cAMP were similar (WT: 1680Ϯ137 fmol/3000 cells; NRG-1 ϩ/Ϫ : 1604Ϯ39 fmol/3000 cells; PϭNS). In WT myocytes, carbachol attenuated isoproterenol-stimulated cAMP levels (isoproterenol: 238Ϯ15% control; isoproterenolϩcarbachol: 170Ϯ15% control; PϽ0.005). In contrast, in NRG-1 ϩ/Ϫ myocytes, carbachol failed to abrogate isoproterenol-stimulated levels (isoproterenol: 244Ϯ7% control; isoproterenolϩcarbachol: 246Ϯ14% control; PϭNS).
Consistent with the reported reduction of neuronal nicotinic receptors in NRG-1 ϩ/Ϫ mice, 12, 13 we observed a decreased level of nicotinic receptor protein in brain lysate of NRG-1 ϩ/Ϫ compared with WT mice (Figure 2A ). However, we did not identify any difference in protein levels of LV muscarinic M 2 receptors ( Figure 2B) , levels of G-protein subunits G␣ i1,2 , G␣ i3 , G␣ o , or levels of eNOS and iNOS (data not shown) in NRG-1 ϩ/Ϫ and WT mice.
Discussion
This study demonstrates that muscarinic receptor stimulation fails to depress contractility during ␤-adrenergic stimulation in cardiomyocytes from mice heterozygous for neuregulin-1 gene deletion (NRG-1 ϩ/Ϫ ). This observation supports a role for neuregulins in maintaining normal parasympathetic modulation of excess ␤-adrenergic stimulation of the heart.
Muscarinic Modulation of ␤-Adrenergic Activation
Classic physiology studies have shown that stimulation of muscarinic receptors by carbachol causes little or no direct negative inotropic effect on ventricular myocardium; 16 however, it induces the reduction of contractility in myocardium stimulated by ␤-adrenergic agonists. 16 -18 Thus, in the normal heart, parasympathetic muscarinic receptor activation plays a cardioprotective role by counterbalancing excess ␤-adrenergic activation. A large body of evidence suggests that excess ␤-adrenergic activation in association with diminished parasympathetic activity is detrimental in heart failure. Studies in dogs showed autonomic imbalance in the early stage of experimental heart failure, 19, 20 and other studies suggest that attenuation of parasympathetic tone precedes sympathetic activation during the development of heart failure. 21 Clinical studies have shown that both low heart rate variability 22, 23 and increased heart rate, 24 indicating increased sympathetic tone and/or decreased parasympathetic tone, are associated with increased risk of sudden death in heart failure. Multiple clinical trials in patients have provided evidence of the beneficial results of ␤-adrenergic blockers on mortality in heart failure. 25 Although therapy aimed at enhancing parasympathetic activation has not been tested in clinical trials, animal studies have shown that vagal stimulation protected against lethal arrhythmias in conscious dogs with healed infarction 26 and improved survival and cardiac remodeling in a rodent model of postinfarction heart failure. 27 In cancer patients treated with the cardiotoxin doxorubicin, pharmacological suppression of neuregulin signaling increases the development of heart failure. 7, 8 The contribution of abnormal neuregulin signaling is not understood and is attributed in part to effects on cardiomyocyte viability and survival. 28 The present study supports the possibility that inhibition of neuregulin signaling may exacerbate heart failure via loss of cardioprotective parasympathetic modulation of the excessive ␤-adrenergic activation that is characteristic of heart failure.
Role of cAMP
The anti-␤-adrenergic effect of parasympathetic stimulation is mediated via coupling of the muscarinic M 2 receptor, the predominant myocardial receptor subtype, with G protein subunits G␣ i and G␣ o . 29 Using G␣ i2 -null mice and G␣ i3 -null mice, Nagata et al 18 reported that G␣ i2 , but not G␣ i3 , is necessary for anti-␤-adrenergic effect in cardiomyocytes. In addition, Valenzuela et al 30 showed that muscarinic inhibition of L-type Ca 2ϩ channels requires muscarinic receptor coupling to G␣ o . Muscarinic receptor stimulation causes inhibition of adenylyl cyclase via G␣ i protein and consequently reduction of intracellular cAMP, which leads to a reduction of L-type Ca 2ϩ current. 31, 32 In the present study, we demonstrated that myocytes of NRG-1 ϩ/Ϫ mice fail to decrease levels of ␤-adrenergic-stimulated cAMP in response to carbachol. Because protein levels of the muscarinic M 2 receptor as well as G␣ i1,2 , G␣ i3 , and G␣ o appear to be similar in WT and NRG-1 ϩ/Ϫ mice, further studies will be necessary to elucidate the defect in coupling of the M 2 receptor to cAMP in this model. Recently, it has been suggested that the attenuation of ␤-adrenergic signaling by muscarinic receptor agonists requires eNOS and NO activation of cGMP, stimulation of type II phosphodiesterase, and subsequent decrease of cAMP. 17 However, others found no alteration in the response to muscarinic stimulation in mice lacking eNOS. 33, 34 Therefore, the importance of NO on muscarinic attenuation of ␤-adrenergic stimulation remains controversial. In the present study, we found no difference in protein levels of eNOS and iNOS between NRG-1 ϩ/Ϫ and WT mice, but we did not measure NO production.
Study Limitations
Although the M 2 receptor is the predominant receptor subtype expressed in myocardium, M 1 , M 3 , M 4 , and M 5 subtypes have also been identified. 35 ,36 M 1 , M 3 , and M 5 receptors couple preferentially with G q/11 protein and activate the phospholipase C-diacylglycerolinositolphosphate system. 37 Additionally, stimulation of M 2 receptor may result in activation of G protein ␣-subunit and subsequent release of the ␤␥-complex, which is able to activate the phospholipase C pathway. 38 Further studies will be needed to elucidate the relationship between neuregulins and these signaling pathways in normal and NRG-1 ϩ/Ϫ mice and to explore the contribution of neuregulins to cardiac parasympathetic activation in heart failure.
